197 related articles for article (PubMed ID: 15038952)
1. Evaluation of an algorithm for switching from IV to PO therapy in clinical practice in patients with community-acquired pneumonia.
van der Eerden MM; de Graaff CS; Vlaspolder F; Bronsveld W; Jansen HM; Boersma WG
Clin Ther; 2004 Feb; 26(2):294-303. PubMed ID: 15038952
[TBL] [Abstract][Full Text] [Related]
2. Managing antiinfective therapy of community-acquired pneumonia in the hospital setting: focus on switch therapy.
Ramirez JA
Pharmacotherapy; 2001 Jul; 21(7 Pt 2):79S-82S. PubMed ID: 11446522
[TBL] [Abstract][Full Text] [Related]
3. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.
Drummond MF; Becker DL; Hux M; Chancellor JV; Duprat-Lomon I; Kubin R; Sagnier PP
Chest; 2003 Aug; 124(2):526-35. PubMed ID: 12907538
[TBL] [Abstract][Full Text] [Related]
4. Switching from intravenous to oral antibiotics in hospitalized patients with community-acquired pneumonia: A real-world analysis 2010-2018.
Kimura T; Ito M; Onozawa S
J Infect Chemother; 2020 Jul; 26(7):706-714. PubMed ID: 32284180
[TBL] [Abstract][Full Text] [Related]
5. Community-acquired pneumonia team decreases length of stay in hospitalized, low-risk patients with pneumonia.
Marcos PJ; Restrepo MI; Sanjuàn P; Ferreira-Gonzalez L; Verea-Hernando H
Hosp Pract (1995); 2013 Aug; 41(3):7-14. PubMed ID: 23948616
[TBL] [Abstract][Full Text] [Related]
6. A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
Feagan BG
Pharmacotherapy; 2001 Jul; 21(7 Pt 2):89S-94S. PubMed ID: 11446524
[TBL] [Abstract][Full Text] [Related]
7. Impact and barriers of a pharmacist-led practice with computerized reminders on intravenous to oral antibiotic conversion for community-acquired pneumonia inpatients.
Xu S; Wang X; Song Z; Han F; Zhang C
J Clin Pharm Ther; 2021 Aug; 46(4):1055-1061. PubMed ID: 34101230
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of the treatment and outcome of community-acquired pneumonia according to the Pneumonia Severity Index in VHA hospitals.
Davydov L; Ebert SC; Restino M; Gardner M; Bedenkop G; Uchida KM; Bertino JS
Diagn Microbiol Infect Dis; 2006 Apr; 54(4):267-75. PubMed ID: 16466891
[TBL] [Abstract][Full Text] [Related]
9. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
Lode H; File TM; Mandell L; Ball P; Pypstra R; Thomas M;
Clin Ther; 2002 Nov; 24(11):1915-36. PubMed ID: 12501883
[TBL] [Abstract][Full Text] [Related]
10. [Community-acquired pneumonia: influence of the duration of intravenous antibiotic therapy on hospital stay and the cost-benefit ratio].
Fernández Alvarez R; Gullón Blanco JA; Rubinos Cuadrado G; Jiménez Sosa A; Hernández García C; Medina Gonzálvez A; González Martín I
Arch Bronconeumol; 2001 Oct; 37(9):366-70. PubMed ID: 11674935
[TBL] [Abstract][Full Text] [Related]
11. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
12. Intravenous to Oral Antibiotic Switch Therapy Among Patients Hospitalized With Community-Acquired Pneumonia.
Deshpande A; Klompas M; Guo N; Imrey PB; Pallotta AM; Higgins T; Haessler S; Zilberberg MD; Lindenauer PK; Rothberg MB
Clin Infect Dis; 2023 Jul; 77(2):174-185. PubMed ID: 37011018
[TBL] [Abstract][Full Text] [Related]
13. Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia.
Clark LC; Davis CW
Am J Health Syst Pharm; 2000 Nov; 57 Suppl 3():S10-3. PubMed ID: 11098314
[TBL] [Abstract][Full Text] [Related]
14. Implication of clinical pathway care for community-acquired pneumonia in a community hospital: early switch from an intravenous beta-lactam plus a macrolide to an oral respiratory fluoroquinolone.
Shindo Y; Sato S; Maruyama E; Ohashi T; Ogawa M; Imaizumi K; Hasegawa Y
Intern Med; 2008; 47(21):1865-74. PubMed ID: 18981629
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of pneumonia severity index in hospitalised patients with community-acquired pneumonia.
van der Eerden MM; de Graaff CS; Bronsveld W; Jansen HM; Boersma WG
Respir Med; 2004 Sep; 98(9):872-8. PubMed ID: 15338800
[TBL] [Abstract][Full Text] [Related]
16. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization.
Corrêa JC; Badaró R; Bumroongkit C; Mera JR; Dolmann AL; Juárez Martínez LG; Mayrinck LR; Tamez R; Yang JY
Clin Ther; 2003 May; 25(5):1453-68. PubMed ID: 12867221
[TBL] [Abstract][Full Text] [Related]
17. Outcome predictors of pneumonia in elderly patients: importance of functional assessment.
Torres OH; Muñoz J; Ruiz D; Ris J; Gich I; Coma E; Gurguí M; Vázquez G
J Am Geriatr Soc; 2004 Oct; 52(10):1603-9. PubMed ID: 15450034
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
Patel T; Pearl J; Williams J; Haverstock D; Church D
Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia.
Davis SL; Delgado G; McKinnon PS
Clin Infect Dis; 2005 Jul; 41 Suppl 2():S136-43. PubMed ID: 15942880
[TBL] [Abstract][Full Text] [Related]
20. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS
Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
